SVFCX vs. MANH, NICE, PCTY, KVYO, U, PCOR, DAY, ALTR, CDAY, and TTAN
Should you be buying Smead Value C stock or one of its competitors? The main competitors of Smead Value C include Manhattan Associates (MANH), NICE (NICE), Paylocity (PCTY), Klaviyo (KVYO), Unity Software (U), Procore Technologies (PCOR), Dayforce (DAY), Altair Engineering (ALTR), Ceridian HCM (CDAY), and ServiceTitan (TTAN). These companies are all part of the "computer and technology" sector.
Smead Value C vs. Its Competitors
Manhattan Associates (NASDAQ:MANH) and Smead Value C (NASDAQ:SVFCX) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Manhattan Associates has a net margin of 20.95% compared to Smead Value C's net margin of 0.00%. Manhattan Associates' return on equity of 84.62% beat Smead Value C's return on equity.
In the previous week, Manhattan Associates had 13 more articles in the media than Smead Value C. MarketBeat recorded 13 mentions for Manhattan Associates and 0 mentions for Smead Value C. Manhattan Associates' average media sentiment score of 0.61 beat Smead Value C's score of 0.00 indicating that Manhattan Associates is being referred to more favorably in the media.
Manhattan Associates presently has a consensus price target of $208.88, suggesting a potential upside of 10.33%. Given Manhattan Associates' stronger consensus rating and higher probable upside, research analysts plainly believe Manhattan Associates is more favorable than Smead Value C.
Manhattan Associates has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Smead Value C has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.
Manhattan Associates received 532 more outperform votes than Smead Value C when rated by MarketBeat users. However, 100.00% of users gave Smead Value C an outperform vote while only 63.42% of users gave Manhattan Associates an outperform vote.
Manhattan Associates has higher revenue and earnings than Smead Value C.
98.4% of Manhattan Associates shares are owned by institutional investors. Comparatively, 60.2% of Smead Value C shares are owned by institutional investors. 0.7% of Manhattan Associates shares are owned by insiders. Comparatively, 10.3% of Smead Value C shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Manhattan Associates beats Smead Value C on 13 of the 15 factors compared between the two stocks.
Get Smead Value C News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVFCX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SVFCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SVFCX vs. The Competition
Smead Value C Competitors List
Related Companies and Tools
This page (NASDAQ:SVFCX) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy SVFCX Stock Free SVFCX Stock Alerts